- Molecular NameAtorvastatin
- SynonymAtorvastatin calcium
- Weight558.65
- Drugbank_IDDB01076
- ACS_NO134523-00-5
- Show 3D model
- LogP (experiment)6.36
- LogP (predicted, AB/LogP v2.0)4.82
- pka4.46
- LogD (pH=7, predicted)2.17
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.22
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors4
- No.of HBond Acceptors7
- No.of Rotatable Bonds12
- TPSA111.79
- StatusFDA approved
- AdministrationN/A
- PharmacologyA member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms.
- Absorption_valueN/A
- Absorption (description)Atorvastatin is rapidly absorbed after oral administration, which increases in proportion to the dose administered.
- Caco_2N/A
- Bioavailability12.0
- Protein binding98.0
- Volume of distribution (VD)5.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Blood cells:plasma, 0.25.
- MetabollsmAbsolute bioavailability is approximately 12% due to presystemic clearance in the gastro-intestinal mucosa and metabolism by cytochrome P450 3A4 in the liver. A number of metabolites have been identified, all with inhibitory activity, including 2- and 4-hydroxyatorvastatin, ortho- and para-hydroxylated derivatives and various β-oxidation products.
- Half life19.5 h
- ExcretionAtorvastatin is excreted as metabolites, primarily in bile, with less than 2% of the dose present in urine.
- Urinary Excretion<2
- Clerance29 ml/min/kg
- ToxicityRhabdomyolysis, eye hemorrhages, and liver problems.
- LD50 (rat)N/A
- LD50 (mouse)N/A